Early-stage drug discovery can take years and requires deep expertise in computational chemistry that most biologists don't have. This creates a massive bottleneck in getting new therapies from concept to testing.
In this episode, Ayush Mishra sits down with Javier Tordable, Founder & CEO of Pauling.AI, to explore how AI is automating the most time-intensive parts of drug discovery and why adoption remains the industry's biggest challenge.
You will hear insights on:
Why he left 16 years at Google to focus entirely on pharmaceutical AI
How rational drug design works and where the traditional process breaks down
What Pauling.AI does differently, an AI agent that handles target identification, molecular design, and binding predictions like ChatGPT handles text
The real resistance AI faces from veteran scientists and the uncomfortable truth about generational change in pharma
When we can expect to see the first fully AI-designed drugs receive FDA approval
Where emerging market founders can find datasets when premium pharmaceutical data is locked behind paywalls
What human scientists will always do better than AI, and why that matters
His brutally honest take on the "science advances one funeral at a time" phenomenon
Practical advice for biotech entrepreneurs building AI healthcare companies in Asia and Africa
If you work in pharma R&D, drug discovery, biotech innovation, computational chemistry, or clinical development strategy, this conversation offers an unfiltered view of where AI is actually taking pharmaceutical research.
Javier Tordable's LinkedIn: https://www.linkedin.com/in/jtordable/
Podden och tillhörande omslagsbild på den här sidan tillhör
Ayush Mishra. Innehållet i podden är skapat av Ayush Mishra och inte av,
eller tillsammans med, Poddtoppen.
